Entera Bio Ltd
Company Profile
Business description
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Contact
Minrav Building - Fifth Floor
Kiryat Hadassah
Jerusalem9112002
ISRT: +972 25327151
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
22
Stocks News & Analysis
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
stocks
This might be the best core stock bargain in the US market today
stocks
Data center demand drives strong earnings outlook for SGM
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,544.40 | 68.80 | 0.81% |
| CAC 40 | 7,665.62 | 142.25 | -1.82% |
| DAX 40 | 22,380.19 | 459.37 | -2.01% |
| Dow JONES (US) | 45,577.47 | 443.96 | -0.96% |
| FTSE 100 | 9,918.33 | 145.17 | -1.44% |
| HKSE | 24,670.62 | 606.70 | -2.40% |
| NASDAQ | 21,647.61 | 443.08 | -2.01% |
| Nikkei 225 | 51,534.14 | 1,838.39 | -3.44% |
| NZX 50 Index | 12,887.55 | 102.44 | -0.79% |
| S&P 500 | 6,506.48 | 100.01 | -1.51% |
| S&P/ASX 200 | 8,357.10 | 73.60 | 0.89% |
| SSE Composite Index | 3,896.73 | 60.33 | -1.52% |